China

Bristol-Myers wins the frenzied race to a first approval for a PD-1/L1 checkpoint in China as regulators hustle up a quick OK
Bristol-Myers wins the frenzied race to a first approval for a PD-1/L1 checkpoint in China as regulators hustle up a quick OK
Endpoints
Bristol-Myers Squibb
Opdivo
China
Flag link:
Sound familiar? China/US biotech hybrid lands rights to cancer drugs, cash and a team of development vets to launch Oncologie
Sound familiar? China/US biotech hybrid lands rights to cancer drugs, cash and a team of development vets to launch Oncologie
Endpoints
China
Asia
Oncologie
Flag link:
Roche scrambles to boost Herceptin supply in China after insurance OK triggers shortage
Roche scrambles to boost Herceptin supply in China after insurance OK triggers shortage
Fierce Pharma
Roche
Herceptin
China
Flag link:
Prepping a drug launch, Zai Lab poaches AstraZeneca’s top cancer drug sales exec in China
Prepping a drug launch, Zai Lab poaches AstraZeneca’s top cancer drug sales exec in China
Endpoints
Zai Lab
AstraZeneca
China
Flag link:
Trump tariffs leave medical device companies in the dark
Trump tariffs leave medical device companies in the dark
Medical Design and Outsourcing
devices
China
Donald Trump
Flag link:
China Focused Brii Biosciences Launches With $260 Million and Team of Industry Veterans
China Focused Brii Biosciences Launches With $260 Million and Team of Industry Veterans
CP Wire
Brii Biosciences
China
GSK
Flag link:
BeiGene Initiates Phase 3 Trial of Pamiparib as Maintenance Therapy in Patients with Ovarian Cancer
BeiGene Initiates Phase 3 Trial of Pamiparib as Maintenance Therapy in Patients with Ovarian Cancer
CP Wire
BeiGene
pamiparib
ovarian cancer
China
clinical trials
Flag link:
China's global investment push opens doors for domestic biotechs
China's global investment push opens doors for domestic biotechs
Biopharma Dive
China
Belt and Road Initiative
biotech
Flag link:
Luye Pharma Buys Rights to Seroquel in China and Other Territories for $538 Million
Luye Pharma Buys Rights to Seroquel in China and Other Territories for $538 Million
CP Wire
AstraZeneca
Luye Pharma Group
China
Seroquel
Seroquel XR
Flag link:
Zoetis doubles down on animal vaccines
Zoetis doubles down on animal vaccines
Biopharma Dive
Zoetis
China
animal health
R&D
vaccines
Flag link:
CANbridge Receives China FDA Approval for Oral Mucositis Therapy
CANbridge Receives China FDA Approval for Oral Mucositis Therapy
CP Wire
CANbridge
China
CFDA
CAN002
oral mucositis
Flag link:
Trump tariffs threaten to cost medical device industry billions
Trump tariffs threaten to cost medical device industry billions
Fierce Biotech
devices
Donald Trump
China
tariffs
Flag link:
Novartis, still embroiled in Greek probe, faces kickback allegation in China—again
Novartis, still embroiled in Greek probe, faces kickback allegation in China—again
Fierce Pharma
Novartis
China
Greece
kickbacks
bribery
Flag link:
Trump Tariffs Target Key Ingredients for Dozens of Drugs
Trump Tariffs Target Key Ingredients for Dozens of Drugs
Bloomberg
Donald Trump
China
tariffs
drug pricing
Flag link:
After a makeover and hiring spree, China’s drug agency is romping and stomping on new reviews and approvals
After a makeover and hiring spree, China’s drug agency is romping and stomping on new reviews and approvals
Endpoints
China
CFDA
Flag link:
Inovio Closes License and Collaboration Agreement with ApolloBio To Develop and Commercialize DNA Immunotherapy product (VGX-3100) in Greater China
Inovio Closes License and Collaboration Agreement with ApolloBio To Develop and Commercialize DNA Immunotherapy product (VGX-3100) in Greater China
CP Wire
Inovio
China
ApolloBio
VGX-3100
DNAi-based therapeutics
HPV
Flag link:
China's Aim to Remove Cancer Drug Taxes May Boost Pfizer, Glaxo
China's Aim to Remove Cancer Drug Taxes May Boost Pfizer, Glaxo
Bloomberg
China
Pfizer
GSK
cancer
taxes
Flag link:
2 Biotech Stocks Near All-Time Highs: Can They Keep Climbing?
2 Biotech Stocks Near All-Time Highs: Can They Keep Climbing?
Motley Fool
biotech
BeiGene
China
Celgene
AnaptysBio
ANB020
eczema
Flag link:
Bye CFDA: China’s drug regulator to take new shape in major government restructuring
Bye CFDA: China’s drug regulator to take new shape in major government restructuring
Endpoints
China
regulatory
CFDA
Flag link:
North of a billion biotech VC dollars to come from C-Bridge, Rothschild as global biopharma capital flows
North of a billion biotech VC dollars to come from C-Bridge, Rothschild as global biopharma capital flows
Endpoints
venture capital
biotech
C-Bridge
Rothschild
China
Europe
Flag link:

Pages